CA2696319C - Method for assaying sepsis in humans - Google Patents
Method for assaying sepsis in humans Download PDFInfo
- Publication number
- CA2696319C CA2696319C CA2696319A CA2696319A CA2696319C CA 2696319 C CA2696319 C CA 2696319C CA 2696319 A CA2696319 A CA 2696319A CA 2696319 A CA2696319 A CA 2696319A CA 2696319 C CA2696319 C CA 2696319C
- Authority
- CA
- Canada
- Prior art keywords
- reg
- psp
- level
- antibody
- sepsis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010040047 Sepsis Diseases 0.000 title claims abstract description 61
- 238000000034 method Methods 0.000 title claims abstract description 46
- 208000014674 injury Diseases 0.000 claims abstract description 45
- 210000002966 serum Anatomy 0.000 claims abstract description 41
- 230000008733 trauma Effects 0.000 claims abstract description 37
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 238000011161 development Methods 0.000 claims abstract description 12
- 102000016997 Lithostathine Human genes 0.000 claims abstract description 11
- 108010014691 Lithostathine Proteins 0.000 claims abstract description 11
- 230000001172 regenerating effect Effects 0.000 claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 claims description 29
- 241000282414 Homo sapiens Species 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 17
- 238000002965 ELISA Methods 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 10
- 238000003118 sandwich ELISA Methods 0.000 claims description 9
- 230000009885 systemic effect Effects 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 8
- 238000004949 mass spectrometry Methods 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 241000700199 Cavia porcellus Species 0.000 claims description 6
- 241000283707 Capra Species 0.000 claims description 5
- 241000283074 Equus asinus Species 0.000 claims description 5
- 241000287828 Gallus gallus Species 0.000 claims description 5
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 5
- 241000700159 Rattus Species 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 238000010208 microarray analysis Methods 0.000 claims description 5
- 206010033627 Pancreatic injury Diseases 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000012086 standard solution Substances 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 241000700198 Cavia Species 0.000 claims description 2
- 241000283086 Equidae Species 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 238000002038 chemiluminescence detection Methods 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 230000018109 developmental process Effects 0.000 claims 2
- 101000637771 Homo sapiens Solute carrier family 35 member G1 Proteins 0.000 claims 1
- 102000053339 human SLC35G1 Human genes 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 12
- 102100032752 C-reactive protein Human genes 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000006378 damage Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 108010048233 Procalcitonin Proteins 0.000 description 9
- 210000001124 body fluid Anatomy 0.000 description 9
- 239000010839 body fluid Substances 0.000 description 9
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 101000899095 Homo sapiens BPI fold-containing family A member 2 Proteins 0.000 description 6
- 101001136670 Homo sapiens Persephin Proteins 0.000 description 6
- 101000615965 Homo sapiens Phosphoserine phosphatase Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 102000055841 human BPIFA2 Human genes 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 208000004221 Multiple Trauma Diseases 0.000 description 4
- 208000023637 Multiple injury Diseases 0.000 description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000235058 Komagataella pastoris Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- -1 1L-6 Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 101150045458 KEX2 gene Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108010038049 Mating Factor Proteins 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000002565 Open Fractures Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 102000008080 Pancreatitis-Associated Proteins Human genes 0.000 description 1
- 108010074467 Pancreatitis-Associated Proteins Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091058544 REG family proteins Proteins 0.000 description 1
- 101100065094 Rattus norvegicus Egr3 gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 210000003134 paneth cell Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/474—Pancreatic thread protein; Reg protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Peptides Or Proteins (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07017539.3 | 2007-09-07 | ||
| EP07017539 | 2007-09-07 | ||
| PCT/EP2008/007158 WO2009030456A1 (en) | 2007-09-07 | 2008-09-02 | Method for assaying sepsis in humans |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2696319A1 CA2696319A1 (en) | 2009-03-12 |
| CA2696319C true CA2696319C (en) | 2021-02-02 |
Family
ID=40040164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2696319A Active CA2696319C (en) | 2007-09-07 | 2008-09-02 | Method for assaying sepsis in humans |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8435755B2 (OSRAM) |
| EP (1) | EP2185937B2 (OSRAM) |
| JP (1) | JP5048838B2 (OSRAM) |
| CN (1) | CN101796418B (OSRAM) |
| AT (1) | ATE514950T1 (OSRAM) |
| AU (1) | AU2008295046B2 (OSRAM) |
| CA (1) | CA2696319C (OSRAM) |
| DK (1) | DK2185937T4 (OSRAM) |
| ES (1) | ES2368877T5 (OSRAM) |
| NZ (1) | NZ583474A (OSRAM) |
| PL (1) | PL2185937T5 (OSRAM) |
| PT (1) | PT2185937E (OSRAM) |
| WO (1) | WO2009030456A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2577316T3 (en) | 2010-05-31 | 2017-05-08 | Univ Hospital Of Basel | Procedure for testing for lower respiratory tract infections or inflammation |
| HUE050775T2 (hu) | 2010-08-31 | 2021-01-28 | Univ Otto Von Guericke Magdeburg | Eljárás fertõzõ peritonitis diagnosztizálására, és súlyosságának és kimenetelének elõre történõ meghatározására emberben |
| US20130004968A1 (en) * | 2010-09-22 | 2013-01-03 | Robert Webber | Sepsis blood biomarker system |
| WO2014009480A1 (en) | 2012-07-12 | 2014-01-16 | Universität Zürich | Method for assaying sepsis and outcome in humans by detection of psp/reg |
| US20140120174A1 (en) * | 2012-10-30 | 2014-05-01 | Lascco, Sa | Methods of prognosis and diagnosis of sepsis |
| US20150362509A1 (en) * | 2013-01-28 | 2015-12-17 | Vanderbilt University | Method for Differentiating Sepsis and Systemic Inflammatory Response Syndrome (SIRS) |
| EP2813852A3 (en) | 2013-06-11 | 2015-03-25 | University Of Zurich | Method for detecting the development of an infection in humans |
| CN106367488A (zh) * | 2016-08-29 | 2017-02-01 | 北京泱深生物信息技术有限公司 | Letmd1在脓毒症诊断中的应用 |
| EP3438668A1 (en) | 2017-08-04 | 2019-02-06 | B.R.A.H.M.S GmbH | Diagnosis and risk stratification of fungal infections |
| EP3971573A1 (en) | 2017-09-13 | 2022-03-23 | B.R.A.H.M.S GmbH | Proadrenomedullin as a marker for abnormal platelet levels |
| EP3502706A1 (en) | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
| CN108181472B (zh) * | 2018-03-05 | 2020-07-21 | 吉林大学 | 昆虫细胞表达psp为校准品的检测psp试剂盒 |
| EP3578989A1 (en) | 2018-06-06 | 2019-12-11 | B.R.A.H.M.S GmbH | Pro-adm for prognosis of trauma-related complications in polytrauma patients |
| FR3087338B1 (fr) * | 2018-10-22 | 2020-10-09 | Amadeite | Extrait d'algues pour son utilisation pour le traitement ou la prevention de l'immunosuppression post-traumatique |
| WO2022096916A1 (en) * | 2020-11-03 | 2022-05-12 | Abionic Sa | Method for assessing the severity of sars |
| JP2024542180A (ja) * | 2021-11-25 | 2024-11-13 | アビオニック・ソシエテ・アノニム | 抗生物質投与の管理方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4837990A (en) * | 1988-12-21 | 1990-07-10 | General Hospital Corporation, The | Method of detecting neurological disease or dysfunction |
| GB9613629D0 (en) * | 1996-06-28 | 1996-08-28 | Univ Leeds | Reg gene expression in cancer tissue |
| ATE272214T1 (de) * | 2001-12-04 | 2004-08-15 | Brahms Ag | Verfahren zur diagnose von sepsis unter bestimmung von s100b |
| DE50105971D1 (de) * | 2001-12-04 | 2005-05-25 | Brahms Ag | Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 125 |
| EP1318404B1 (de) * | 2001-12-04 | 2004-07-28 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 19-9 |
| ATE282831T1 (de) * | 2001-12-04 | 2004-12-15 | Brahms Ag | Verfahren zur diagnose von sepsis unter bestimmung löslicher cytokeratinfragmente |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| JP2004194534A (ja) * | 2002-12-17 | 2004-07-15 | Sumitomo Pharmaceut Co Ltd | 炎症性腸疾患疾患マーカーおよびその利用 |
| DE602004015064D1 (de) * | 2003-01-06 | 2008-08-28 | Wyeth Corp | Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs |
| WO2004087874A2 (en) * | 2003-03-28 | 2004-10-14 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| US20070224638A1 (en) * | 2006-03-27 | 2007-09-27 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
| DK2577316T3 (en) * | 2010-05-31 | 2017-05-08 | Univ Hospital Of Basel | Procedure for testing for lower respiratory tract infections or inflammation |
-
2008
- 2008-09-02 PL PL08801791T patent/PL2185937T5/pl unknown
- 2008-09-02 US US12/676,650 patent/US8435755B2/en active Active
- 2008-09-02 WO PCT/EP2008/007158 patent/WO2009030456A1/en not_active Ceased
- 2008-09-02 EP EP08801791.8A patent/EP2185937B2/en active Active
- 2008-09-02 JP JP2010523316A patent/JP5048838B2/ja active Active
- 2008-09-02 PT PT08801791T patent/PT2185937E/pt unknown
- 2008-09-02 CN CN2008801058553A patent/CN101796418B/zh active Active
- 2008-09-02 AT AT08801791T patent/ATE514950T1/de active
- 2008-09-02 ES ES08801791.8T patent/ES2368877T5/es active Active
- 2008-09-02 AU AU2008295046A patent/AU2008295046B2/en active Active
- 2008-09-02 NZ NZ583474A patent/NZ583474A/en unknown
- 2008-09-02 CA CA2696319A patent/CA2696319C/en active Active
- 2008-09-02 DK DK08801791.8T patent/DK2185937T4/da active
-
2013
- 2013-03-29 US US13/853,514 patent/US9857381B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101796418A (zh) | 2010-08-04 |
| EP2185937B1 (en) | 2011-06-29 |
| DK2185937T4 (da) | 2014-10-20 |
| EP2185937B2 (en) | 2014-07-16 |
| US9857381B2 (en) | 2018-01-02 |
| JP2010538282A (ja) | 2010-12-09 |
| PL2185937T3 (pl) | 2012-02-29 |
| PL2185937T5 (pl) | 2014-12-31 |
| US20100222223A1 (en) | 2010-09-02 |
| ES2368877T3 (es) | 2011-11-23 |
| AU2008295046B2 (en) | 2013-08-01 |
| CA2696319A1 (en) | 2009-03-12 |
| US8435755B2 (en) | 2013-05-07 |
| AU2008295046A1 (en) | 2009-03-12 |
| NZ583474A (en) | 2011-07-29 |
| DK2185937T3 (da) | 2011-09-12 |
| ES2368877T5 (es) | 2014-10-20 |
| EP2185937A1 (en) | 2010-05-19 |
| WO2009030456A1 (en) | 2009-03-12 |
| ATE514950T1 (de) | 2011-07-15 |
| CN101796418B (zh) | 2013-05-01 |
| US20130203612A1 (en) | 2013-08-08 |
| JP5048838B2 (ja) | 2012-10-17 |
| PT2185937E (pt) | 2011-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2696319C (en) | Method for assaying sepsis in humans | |
| EP1709444B1 (en) | Method of diagnosing infectious disease by measuring the level of soluble trem-1 in a sample | |
| JP5011410B2 (ja) | 生体液のプロテオーム分析 | |
| ES2897419T3 (es) | Procedimientos de predicción del riesgo de un resultado clínico adverso | |
| EP2612152B1 (en) | Method to diagnose infectious peritonitis and predict the severity and outcome thereof in humans. | |
| JP2019531467A (ja) | 有害事象を示すマーカーとしてのヒストンおよび／またはｐｒｏＡＤＭ | |
| US11402390B2 (en) | Method for assaying lower respiratory tract infection or inflammation | |
| EP2673646B1 (en) | Diagnostic method for urinary tract infection | |
| HK1215731A1 (zh) | 借助抗利尿激素原对呼吸道和肺部的感染及慢性病的诊断和风险性分级 | |
| US20030175713A1 (en) | Method for diagnosis of inflammatory diseases using CALGRANULIN C | |
| Palmiere et al. | Pancreatic stone protein as a postmortem biochemical marker for the diagnosis of sepsis | |
| EP3087395B1 (en) | Method for detecting a systemic inflammation and test system | |
| EP2813852A2 (en) | Method for detecting the development of an infection in humans | |
| CN116298327A (zh) | 用于诊断脓毒症的标志物及其用途 | |
| Chu et al. | Diagnostic value of apoptosis biomarkers in severe sepsis-A pilot study | |
| Shi et al. | Relationships between serum procalcitonin level, severity and different stresses of non-septic critically ill patients | |
| EP1608968A1 (en) | Assessment method | |
| CN113495155A (zh) | 分诊方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130820 |